Profile data is unavailable for this security.
About the company
WuXi XDC Cayman Inc is an investment holding company principally engaged in the provision of comprehensive contract research, development and manufacturing organization (CRDMO) services for antibody drug conjugate (ADC) and other bioconjugates. The Company's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The Company provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The Company principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.
- Revenue in HKD (TTM)5.75bn
- Net income in HKD1.50bn
- Incorporated2020
- Employees2.27k
- LocationWuXi XDC Cayman IncNo. 11 Xinhui Ring Road, Xinwu DistrictWUXI KY1-1104ChinaCHN
- Websitehttps://wuxixdc.com/
More ▼
Mergers & acquisitions
| Acquired company | 2268:HKG since announced | Transaction value |
|---|---|---|
| BioDlink International Co Ltd | -12.47% | 398.01m |
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics, Inc. | 9.71bn | 4.65bn | 70.70bn | 350.00 | 16.17 | 17.94 | 13.35 | 7.28 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Axsome Therapeutics Inc | 4.39bn | -1.79bn | 72.08bn | 683.00 | -- | 124.83 | -- | 16.43 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Krka dd Novo Mesto | 18.64bn | 3.70bn | 72.11bn | 13.11k | 18.20 | 3.16 | 15.80 | 3.87 | 13.02 | 13.02 | 65.60 | 75.06 | 0.6947 | 1.31 | 3.44 | 156,823.60 | 13.79 | 12.80 | 16.67 | 15.31 | 57.71 | 57.39 | 19.85 | 19.11 | 2.57 | -- | 0.0082 | 59.40 | 5.71 | 5.04 | 13.71 | 7.77 | 0.8404 | 14.19 |
| Eisai Co Ltd | 41.36bn | 2.19bn | 74.02bn | 13.51k | 32.70 | 1.57 | 17.28 | 1.79 | 151.67 | 151.67 | 2,866.61 | 3,153.46 | 0.5537 | 0.7996 | 3.33 | 59,839,040.00 | 3.04 | 3.81 | 4.22 | 5.14 | 77.75 | 77.47 | 5.48 | 6.44 | 1.54 | -- | 0.2015 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Mankind Pharma Ltd | 11.95bn | 1.53bn | 74.07bn | 27.00k | 48.41 | -- | 32.05 | 6.20 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Shanghai Fosun Pharmaceutical (Group) | 44.79bn | 3.72bn | 75.72bn | 40.56k | 21.72 | 1.49 | -- | 1.69 | 1.24 | 1.24 | 14.91 | 17.99 | 0.3389 | 2.95 | 4.71 | 975,138.50 | 3.47 | 3.90 | 5.95 | 6.49 | 46.84 | 48.81 | 10.24 | 9.85 | 0.7214 | -- | 0.3806 | 32.08 | -0.8028 | 7.52 | 16.08 | -3.57 | 2.17 | -3.88 |
| Jazz Pharmaceuticals PLC | 32.50bn | -2.88bn | 78.98bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Zydus Lifesciences Ltd | 22.52bn | 4.26bn | 79.98bn | 27.92k | 18.76 | -- | 15.26 | 3.55 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| WuXi XDC Cayman Inc | 5.75bn | 1.50bn | 81.33bn | 2.27k | 55.96 | 9.24 | 49.34 | 14.13 | 1.16 | 1.16 | 4.43 | 7.00 | 0.5687 | 21.58 | 3.31 | 2,819,338.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
| Lupin Ltd | 21.36bn | 3.73bn | 87.20bn | 19.98k | 23.42 | 5.14 | 17.95 | 4.08 | 94.43 | 94.43 | 540.38 | 429.82 | 0.8393 | 1.25 | 4.34 | 12,388,350.00 | 14.74 | 4.53 | 21.74 | 7.16 | 71.70 | 59.70 | 17.57 | 5.95 | 1.32 | 110.56 | 0.2396 | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Orion Oyj | 15.11bn | 2.91bn | 87.88bn | 4.03k | 30.14 | 9.28 | 26.09 | 5.82 | 2.23 | 2.23 | 11.59 | 7.24 | 0.9707 | 1.55 | 6.55 | 419,768.00 | 18.66 | 20.14 | 26.08 | 24.67 | 59.66 | 59.72 | 19.22 | 21.16 | 1.19 | 101.62 | 0.234 | 84.25 | 29.65 | 7.97 | 52.17 | 10.48 | 19.14 | 1.80 |
| Avidity Biosciences Inc | 163.11m | -4.30bn | 88.18bn | 391.00 | -- | 5.67 | -- | 540.64 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 24.18bn | 4.07bn | 90.00bn | 3.04k | 22.46 | 1.90 | 19.09 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Dr Reddy's Laboratories Ltd | 29.93bn | 4.81bn | 91.61bn | 26.94k | 19.08 | -- | 14.19 | 3.06 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
Data as of Feb 13 2026. Currency figures normalised to WuXi XDC Cayman Inc's reporting currency: Hong Kong Dollar HKD
8.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 15.01m | 1.20% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 14.88m | 1.19% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 13.40m | 1.07% |
| Morgan Stanley & Co. International Plcas of 15 Jan 2025 | 12.77m | 1.02% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 12.56m | 1.00% |
| Morgan Stanley & Co. LLCas of 15 Jan 2025 | 10.90m | 0.87% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 8.57m | 0.68% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 6.60m | 0.53% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 5.95m | 0.47% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 5.47m | 0.44% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
